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bDepartment of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA
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1. Introduction
Otitis media (OM) is one of the most frequent diseases afﬂicting
humans and is prevalent in both developed and developing
countries.1 It represents a signiﬁcant healthcare burden, with over
5 billion dollars spent every year in the world on this disease.2 The
term ‘otitis media’ covers a wide spectrum of disease, and is used to
describe illnesses with predominantly middle ear symptoms. With
its diverse clinical syndromes and affected host groups, OM remains
one of the challenging diseases encountered in clinical practice.3 It is
the leading cause of hearing loss and is associated with signiﬁcant
morbidity.4–7 Children are at greater risk and suffer most frequently
from OM. This can cause serious deterioration in the quality of life.8
Studies show that 80% of children will have experienced at least one
episode of OM by their third birthday and 40% will have six or more
recurrences by the age of 7 years.9 OM is also the predominant
reason for antibiotic prescription.10 It is the primary indication for
tympanostomy tube insertion, which is the most commonly
performed operation on children.11
The pathogenesis of OM is thought to be multifactorial and
includes Eustachian tube dysfunction, allergy, viral and bacterial
invasion, reduced ciliary function of both the middle ear and
Eustachian tube mucosa, smoke exposure, gastro-esophageal reﬂux,
and autoimmune and many other etiologies not yet fully under-
stood.12OM can lead to life-threatening extracranial and intracranial
complications.13 Every year 28,000 deaths are attributable to OM
complications, mainly through meningitis and brain abscess.14,15
There are two main entities of OM: acute otitis media (AOM)
and chronic suppurative otitis media (CSOM).16 AOM is deﬁned as
the presence of inﬂammation in the middle ear accompanied by
the rapid onset of signs and symptoms of an ear infection.
Streptococcus pneumoniae, Haemophilus inﬂuenzae, and Moraxella
catarrhalis are the most common causative agents of AOM.
Despite antibiotic therapy, AOM can progress to CSOM,
characterized by the persistent infection and inﬂammation of
the middle ear and mastoid air cells. This condition typically
involves a perforation of the tympanic membrane, with intermit-
tent or continuous otorrhea.17 As chronic otomastoiditis and
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Eustachian tube dysfunction persist, the tympanic membrane is
weakened, which increases the likelihood of an atelectatic ear or
cholesteatoma formation. The presence of mucin prevents the
transmission of sound waves from the middle ear to the inner ear,
leading to conductive hearing loss. Pseudomonas aeruginosa and
Staphylococcus aureus are the most common pathogens implicated
in CSOM.18–21
Host resistance against pathogens depends on a complex
interplay of innate and adaptive immune mechanisms. The innate
immune system provides a ﬁrst-line, non-speciﬁc defense mecha-
nism, in contrast to the adaptive immune process, which is
pathogen-speciﬁc and requires sensitization. Innate immunity also
stimulates and modulates adaptive immune responses. The present
review is focused on the role of the innate immune system in OM,
speciﬁcally the role of middle ear epithelial cells, neutrophils,
macrophages, ﬁbroblasts, mast cells, and natural killer cells in
protecting the middle ear against pathogens (Figure 1). The innate
immune system detects microbial infection and uses pattern
recognition receptors (PRRs) to recognize the molecular signature
of pathogens, known as pathogen-associated molecular patterns
(PAMPs).22 PRRs include toll-like receptors (TLRs), cytoplasmic
nucleotide-binding oligomerization domain (NOD)-like receptors
(NLRs), retinoic acid-inducible gene (RIG-I), and C-type lectin
receptors (CLRs). The role of these PRRs in OM is also discussed.
2. Epithelial cells
The epithelial lining of the middle ear contains several key
defense mechanisms including the presence of the mucociliary
apparatus, trapping function of mucous glycoproteins and
surfactants, ability to secrete innate defense molecules such as
defensins, interferons, lactoferrin, and nitric oxide, and antibody
production through the adaptive immune response. Middle ear
epithelial cells also express PRRs like TLRs, which help in sensing
pathogens through PAMPs.22
2.1. Defensins
The middle ear epithelial cells primarily release beta
defensins, which are cationic proteins with antimicrobial
function against a wide range of viruses, bacteria, fungi, and
protozoa.23 Their major antimicrobial mechanism is thought to
be through the formation of a pore into the microbial membrane.
However, some defensins are known to stimulate pro-inﬂamma-
tory cytokines/chemokines, to act as chemoattractants for
neutrophils, mast cells, T cells, and dendritic cells, and to
directly inhibit bacterial toxins.23 The up-regulated expression of
mouse b-defensins 2, 3, and 4 has been demonstrated in the
tubotympanums in experimental OM, while no such up-
regulation was seen in the middle ears of healthy controls.24
Human b-defensin 2 (HBD2) is seen to be up-regulated in the
middle ear response to bacteria and cytokines like non-typeable
Haemophilus inﬂuenzae (NTHi) and interleukin (IL)-1a.25,26 HBD2
expression occurs in response to NTHi binding to toll-like
receptor 2 (TLR2) and subsequent activation of a toll/IL-1
receptor MyD88-IRAK1-TRAF6-MKK3/6-p38 mitogen activated
protein (MAP) kinase signal transduction pathway.25,26 Beta-
defensin 2 production has been demonstrated to be greatest
when the p38 MAP kinase pathway acts synergistically with the
MyD88-independent Raf-MEK1/2-ERK MAP kinase pathway
stimulated by IL-1a. 25,26 In addition, the b-defensin 2 produc-
tion in epithelial cells is up-regulated with exposure to tumor
necrosis factor alpha (TNF-a) and lipopolysaccharide (LPS).27
The recombinant human b-defensin 3 (rhBD-3) plays a critical
role in eliminating NTHi, and its function has been shown to be
inhibited by bioﬁlms.28
Figure 1. Middle ear innate immunity. The middle ear is lined by epithelial cells, which can provide protection by secreting antimicrobial molecules, or through toll-like
receptors (TLRs). The middle ear also possesses innate immune cells such as neutrophils, macrophages, dendritic cells, mast cells, and natural killer cells providing defense
against intruding pathogens.
R. Mittal et al. / International Journal of Infectious Diseases 29 (2014) 259–267260
2.2. SPLUNC1
Another important molecule that has been demonstrated to
play a role in OM is SPLUNC1. It is a predominant component of the
surface liquid that covers the mucosal surfaces of the human
respiratory tract. SPLUNC1 has broad-spectrum antimicrobial
activity and reduces bioﬁlm formation by P. aeruginosa, supporting
the assertion that this molecule functions in host defense.29–31
SPLUNC1 can also act as a chemoattractant that recruits
macrophages and neutrophils to the site of infection.32 It functions
as a surfactant to reduce surface tension at an air–liquid interface
in the upper airway, including the Eustachian tube, and acts as a
liquid-volume sensor to regulate membrane ion channels.
Although the loss of SPLUNC1 has been shown not to impact
the survival of NTHi, it has been found to be essential in the
maintenance of middle ear ﬂuid pressure and efﬁcient mucociliary
clearance. This ﬁnding has also been demonstrated in a chinchilla
model that lacks the expression of SPLUNC1 ortholog.33
2.3. Other antimicrobial molecules
Several other antimicrobial molecules from epithelial cell
secretions in OM have been investigated. The administration of
apolactoferrin, the iron-free form of lactoferrin, was shown to
signiﬁcantly reduce bacterial counts and the number of inﬂam-
matory cells in a chinchilla model of S. pneumoniae-induced OM.34
It has also been shown that mammalian chitinase and chitotrio-
sidase are overexpressed in adenoidal histiocytes and vascular
endothelial cells in OM.35 This suggests that dysregulation of
chitin-containing pathogens may play a role in OM.
2.4. Mucin
Mucins are high molecular weight glycoproteins (2–30 MDa)
that are implicated in a variety of pathological conditions.36,37
Variation in the quantity and character of middle ear secretions,
and speciﬁcally mucin secretion, is known to be important in the
pathophysiological mechanisms of OM. Mucins are the only
component of middle ear effusions responsible for its viscous
properties, and an over-production of these viscous mucins can
prevent normal mucociliary clearance.
The persistent accumulation of mucin in the middle ear cavity is
likely to involve extensive proliferation of mucous cells and
associated mucosal metaplasia. Mice middle ear infected with
NTHi resulted in mucosal metaplasia and overexpression of Cxcl2,
a major inﬂammatory cell recruiter, thus delaying resolution of
infection.38 P. aeruginosa exotoxin A promotes metaplasia, necro-
sis, and apoptosis of epithelial cells of the middle ear, thus
exposing the submucosal and lamina propria layers, perhaps
leading to inner ear infection and damage.39 Molecular analyses
have shown that TNF-a and retinoic acid act synergistically with
Math1, a transcription factor essential for differentiation of
epithelial cells into mucosal cells, to transform mouse middle
ear epithelial cells into metaplastic mucous-like cells.40
The overproduction of mucin by epithelial cells leads to
CSOM. In humans, 19 mucin genes have been identiﬁed. Among
these, MUC2, MUC5AC, and MUC5B have been shown to play an
important role in the pathogenesis of OM.41–43 Abnormally high
levels of mucin proteins have been demonstrated in middle
ear effusions of CSOM patients.44 This presence of mucin prevents
the transmission of sound waves from the middle ear to the inner
ear, hence leading to conductive hearing loss. However, the
molecular mechanisms underlying mucin overproduction by
human middle ear epithelial cells (HMEECs) during CSOM are
still unknown. We have observed, using scanning electron
microscopy, that P. aeruginosa binds and adheres to HMEECs
(Figure 2).45 Transmission electron microscopy demonstrated P.
aeruginosa internalization inside HMEECs enclosed in membrane-
bound vacuoles (Figure 3).45 However, how this adhesion and
subsequent internalization leads to mucin up-regulation needs to
be explored in future studies.
2.5. Lysozyme
Various cells of the human airway, including surface epithelial
cells, have been shown to produce lysozyme, an antimicrobial
innate immune molecule that degrades the peptidoglycan of the
bacterial cell wall.46 It is particularly found in the tubotympanum
of mammals and plays a signiﬁcant role in OM.47 Lysozyme and
HBD2 have synergistic killing effects against S. pneumoniae.48
Lysozyme M knock-out mice are more susceptible to S. pneumoniae
infection, thus suggesting the role of lysozyme in host defense.49
2.6. Toll-like receptors (TLRs)
There are at least 10 different TLRs found on the surface
of epithelial cells of the human middle ear. TLRs contain an
N-terminal extracellular leucine-rich repeat domain and a cyto-
plasmic toll/IL-1 receptor domain. TLR molecules provide protec-
tion against infection by recognizing intruding pathogens through
Figure 2. Pseudomonas aeruginosa binds to human middle ear epithelial cells
(HMEECs). Scanning electron micrograph showing adhesion of P. aeruginosa to
HMEECs. The micrograph was pseudo-colored using Adobe photoshop software.
Arrows indicate bacteria. Scale bar 5 mm.
Figure 3. Pseudomonas aeruginosa invades human middle ear epithelial cells
(HMEECs). Transmission electron micrograph demonstrating internalization of P.
aeruginosa inside HMEECs. Arrow indicates bacteria. Scale bar 1 mm.
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their invariant PAMPS and then mobilizing appropriate immune
defenses.50,51 The activation of most TLRs results in downstream
activation of the mitogen activated protein kinase (MAPK) or the
nuclear factor kappa B (NF-kB)-dependent cell signaling cascades,
thus leading to further activation of immune responses
(Figure 4).52
In OM, NTHi is associated with several molecular patterns that
function as TLR ligands. NTHi cell surface peptidoglycans and the
associated proteins such as outer membrane protein (OMP) P6
serves as a ligand for TLR2.53 Another notable example is
lipooligosaccharide (LOS), which serves as a ligand for TLR2 and
TLR4.54 Not surprisingly, polymorphisms in the gene encoding for
TLR4 have been associated with recurrent acute OM.55 When
infected with NTHi, TLR4 knock-out mice had a worse mucosal
immune response as compared to wild-type mice.56 These TLR4
knock-out mice had inferior immune responses with regards to
mucosal IgA, systemic IgG, and Th1 cells.56 NTHi and its various
immunogenic molecules have been shown not only to directly
activate TLR, but to up-regulate TLR2 gene expression in middle ear
epithelial cell lines.57 Patients with chronic middle ear disease like
CSOM have been shown to exhibit lower mRNA levels of TLR4,
TLR5, and TLR7 than a control group.58 A recent report has further
conﬁrmed these ﬁndings, demonstrating lower mRNA and protein
levels of TLR2, TLR4, and TLR5 in middle ear mucosa of CSOM
patients.59 The down-regulation of TLR expression during OM can
lead to inefﬁcient host defense in the middle ear. This can cause
repeated infections and persistent inﬂammations, eventually
leading to recurrent, persistent suppurative chronic middle ear
diseases.
3. DNA sensors
Microbial and other forms of non-self DNA can also serve as
PAMPs.60 DNA sensors like TLR9 recognize unmethylated
cytidine–phosphate–guanosine (CpG) motifs that are common
in bacterial, but not mammalian, DNA.61 TLR9 access to bacterial
DNA is further enhanced by the nuclear high-mobility group
box 1 protein (HMGB1).62 Like other TLRs, TLR9 utilizes the TLR
adaptor molecule MyD88, which leads to the production of
proinﬂammatory cytokines via the activation of NF-kB
(Figure 4).61 Besides TLR9, there are six intracellular receptors
that have also been implicated in cytosolic DNA sensing in the
innate immune response. These include DNA-dependent activa-
tor of interferon (IFN) regulatory factors (DAI) (also called Z-DNA
binding protein 1, ZBP1), absent in melanoma 2 (AIM2), RNA
polymerase III (Pol III), leucine-rich repeat (in Flightless I)
interacting protein-1 (Lrrﬁp1), DExD/H box helicases (DHX9 and
DHX36), and most recently, the IFN inducible protein IFI16.63–70
These DNA sensors play a crucial role in the pathogenesis of
OM. OM-prone children show lower TLR9 mRNA levels as
compared to the non-prone group.71 Decreased TLR9 mRNA
expression has also been demonstrated in patients with OM
Figure 4. Toll-like receptor (TLR), nucleotide-binding oligomerization domain (NOD)-like receptor (NLR), and retinoic acid-inducible gene (RIG-I)-like receptor (RLR)
signaling. TLR1 or TLR2 or TLR6 recognizes lipoproteins, TLR3 recognizes dsRNA, TLR4 recognizes bacterial lipopolysaccharide (LPS), TLR5 recognizes bacterial ﬂagellin, TLR7/
8 mediates recognition of ssRNA. TLR9 acts as a DNA sensor and recognizes CpG DNA of bacteria and viruses. The NLR proteins NOD1 and NOD2 are cytosolic pattern
recognition receptors (PRRs). NOD1 senses intracellular meso-diaminopimelic acid (DAP), whereas NOD2 recognizes muramyl dipeptide (MDP). C-type lectin receptor (CLR)
signaling senses carbohydrate recognition domains (CRDs), or structurally similar C-type lectin-like domains (CTLDs). The RLR pathway is involved in the recognition of viral
dsRNA. TLR, NLR, CLR, and RLR signaling causes activation of NF-kB, leading to the production of proinﬂammatory cytokines and the stimulation of immune responses.
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with effusion (OME) with conﬁrmed bacteria in the middle ear
like S. aureus, S. pneumoniae, Bacillus spp, and NTHi.72 TLR9
knock-out mice (TLR9/) demonstrated prolonged and en-
hanced morphological signs of mucosal hyperplasia and inﬂam-
mation in the middle ear, as well as a delay in bacterial clearance
and OM recovery compared to wild-type animals in a murine
model of OM induced by NTHi.73 There was modest up-
regulation of TLR9 signaling genes in this OM mouse model,
which corroborated with the protein levels in both middle ear
mucosal cells and inﬁltrating leukocytes. However, there was
dramatic up-regulation in genes known to be regulated by CpG
DNA, as well as those involved in DNA sensing by DAI, Pol-III, and
AIM2.73 These results suggest that bacterial DNA sensing by the
innate immune system plays an important role in OM resolution
and recovery. However, further studies are warranted to explore
the role of bacterial DNA in the pathogenesis and resolution of
OM. The availability of gene deletion models for other DNA
receptors will help in characterizing the role of DNA sensors in
OM.
4. NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs)
When pathogens bypass the membrane-associated PRRs like
TLRs, they encounter cytoplasmic PRRs such as caspase activation
and recruitment domain (CARD) helicases like RLRs and NLRs.74,75
A wide variety of cells such as macrophages and dendritic cells, as
well as middle ear epithelial cells, express these PRRs.76 RLRs are
expressed ubiquitously at low levels, and their expression is
induced by treatment with type I IFN or a viral infection.77 RLRs like
melanoma differentiation-associated 5 (MDA5) and RIG-I can
recognize dsRNA or ssRNA with 50 triphosphate ends (ppp-ssRNA).
They contain an RNA helicase domain critical for RNA recognition
and two CARDs critical for initiating downstream signaling
pathways.78 NLRs are a group of evolutionarily conserved
intracellular PRRs that play a vital role in innate immunity.76
There are 23 members of NLRs out of which NOD1 and NOD2 have
gained a lot of attention in the pathogenesis of OM.74 RLRs and
NLRs like NOD1 and NOD2 have the ability to initiate and support
robust immune responses through the formation of inﬂamma-
somes and the activation of NF-kB, leading to the production of
inﬂammatory cytokines (Figure 4).76 NLRs and RIG-I play an
important role during OM. Patients with OME show signiﬁcantly
lower levels of NOD1 and NOD2, as well as RIG-I.79 These decreased
PRR expression levels may be associated with the development of
recurrent OME, demonstrating the protective role of NOD1, NOD2,
and RIG-I in OM.
5. C-type lectin receptors (CLRs)
CLRs are a diverse family of soluble and transmembrane
proteins that bind carbohydrates through one or more carbohy-
drate recognition domains, or which possess structurally similar C-
type lectin-like domains that may not necessarily recognize
carbohydrate ligands.80,81 CLRs are divided into 17 groups based
on features including phylogeny and structure.82 Multiple
members of the CLR family are considered to be PRRs due to their
ability to recognize pathogen-associated molecules and induce
intracellular signaling pathways that regulate the immune
response.83 The adaptor molecules in CLR signaling like Bcl-10
are crucial in innate resistance to bacterial infection and LPS
signaling.84 Bcl-10 is an intracellular NF-kB activator with a CARD
that can form homo-oligomers through CARD–CARD interactions
under appropriate conditions.85 The other CLR members such as
Dec-205 are involved in endocytosis and antigen presentation.86
Triggering receptor expressed on myeloid cells 1 (Trem-1) CLR is
up-regulated by bacterial LPS and helps in the activation of
neutrophils and monocytes.87 It plays a crucial role in the
production of cytokines and chemokines as well as up-regulating
adhesion molecules.88 The role of these CLRs in the pathogenesis of
OM has only begun to be elucidated. Patients with OME
demonstrate higher mRNA levels of CLRs or CLR adaptor molecules
such as dectin-1, MR1, MR2, DC-SIGN, Syk, Card-9, Bcl-10, Malt-1,
Src, Dec-205, galectin-1, Tim-3, Trem-1, and DAP-12 in middle ear
effusions.89 The increased expression of CLRs and their adaptor
molecules like Dec-205, Bcl-10, Tim-3, and Trem-1 mRNA have
also been observed in chronic OM with cholesteatoma.90 However,
further studies are warranted to assess the protein expression of
CLRs and their association with the pathogenesis of OM.
6. Neutrophils
Neutrophil involvement in OM has been a topic of increased
interest over the past few years. Neutrophils, or polymorphonu-
clear granulocytes (PMNs), are the most abundant leukocytes and
form the ﬁrst line of defense against invading pathogens.91 Recent
research focusing on acute OM caused by NTHi demonstrated the
formation of neutrophil extracellular traps (NETs) by PMNs in
response to bacterial infection.92 NETs are characterized by a
double-stranded DNA lattice decorated with histones and elas-
tase.93–95 NETs are hypothesized to determine bacterial persis-
tence (rather than clearance) by providing a niche within the
middle ear chamber. NETs were found to be positively correlated
with higher bacterial loads within middle ear ﬂuids and surface-
attached communities in the chinchilla infection model.96 The
inability of NETs to clear otopathogens may contribute to
establishing stable bacterial communities in the middle ear.
Bacteria entangled in DNA stranding from NETs can contribute to
effusion viscosity, one of the hallmarks of CSOM. This may also lead
to insufﬁcient penetration of antibiotics and hence failure to clear
infection.
TLRs are also seen to be important in bacterial clearance by
neutrophils during OM. TLR 2, 4, 5, and 9 mRNA expression is up-
regulated in neutrophils infected with M. catarrhalis with and
without pili.97When TLR4 is non-functional in C3H/HeJ mice, NTHi
infections are prolonged and phagocytosis as well as phagosome
maturation in PMNs are impaired.98 Thus, TLR4 appears to be
intimately involved in the bactericidal function of PMNs and plays
a vital role in eradicating NTHi infection in the middle ear.
7. Macrophages
Macrophages play a central role in innate immunity of the
middle ear.99 Macrophages have been shown to be a major cellular
component of middle ear effusions present in humans.100 Middle
ear macrophages harvested from human effusions produce
suppressive factors that lead to a hyporesponsiveness of lympho-
cytes to several mitogens.101 This may contribute to the chronicity
of OM by promoting ineffective elimination of bacteria. It has also
been shown that macrophages recruited to the middle ear are
functional and capable of discriminate phagocytosis and intracel-
lular killing of bacteria.102 However, S. pneumoniae types 14 and
19F, which are associated with the highest relapse frequency in
cases of acute OM, were found to be the most resistant to
phagocytosis. The clinical isolates of NTHi obtained from children
with OM have also been demonstrated to survive in macro-
phages.103 This ability may enable NTHi to gain an intracellular
niche within its host and contribute to the observed frequency of
recurrent infection. The relative importance of macrophage
function in defense of the middle ear, therefore, may be dependent
on the causative agent. Inefﬁcient phagocytosis or intracellular
killing and/or incomplete digestion of bacteria by middle ear
phagocytes could lead to bacterial antigens being trapped in the
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middle ear. This could promote middle ear effusions by a sustained
release of inﬂammatory mediators or immune injury. Further
studies are warranted to characterize the role of bacterial and host
factors leading to the survival of OM pathogens inside macro-
phages.
8. Dendritic cells/Langerhans cells
Dendritic cells (DCs) are antigen-presenting cells (APCs) and
play an important role in the orchestration of immune
responses.104,105 The epithelial residents of DCs are Langerhans
cells (LCs), which serve as the ‘sentinels’ of the mucosa.106 LCs are
capable of engaging and internalizing a wide variety of pathogens.
The normal tympanic membrane in the ear contains abundant DCs/
LCs.107 These tympanic membrane DCs/LCs have also been shown
to have the potential to migrate and to efﬁciently sensitize T
cells.107 A signiﬁcant increase in the number of DCs/LCs in CSOM as
compared with that in the normal tympanic membrane has been
reported in animal models and human patients.108,109 An increase
in the size and more branching of LCs has also been observed in
OM.110 However the exact function of DCs/LCs in the middle ear
under normal and OM conditions has yet to be elucidated.
9. Fibroblasts
Fibroblasts are the most common cells of connective tissue and
synthesize the extracellular matrix and collagen. They are ‘sentinel
cells’ capable of producing various immune modulators such as
peptide growth factors, cytokines, chemokines, and low molecular
weight inﬂammatory mediators. In OM, ﬁbroblasts are largely
responsible for the architectural changes found in the middle ear.
These changes include hyperplasia of the mucosal epithelium as
well as subepithelial connective tissue.111–114 During OM, the
middle ear mucosa proliferates into a pseudostratiﬁed ciliated
secretory columnar epithelium. There is signiﬁcant neovascular-
ization, which not only allows for increased thickness but also
provides a means for leukocyte inﬁltration. This process is a
potential factor in middle ear effusion and subsequent tissue
edema formation. During NTHi-induced OM, it appears that the
up-regulation of ﬁbroblast and vascular endothelial growth factors
(FGFs and VEGFs) is responsible for the angiogenesis associated
with these changes.115 It has also been observed that VEGF is a
signiﬁcant mediator of vascular permeability and therefore middle
ear effusion. Further studies are warranted to understand the role
of ﬁbroblasts and underlying signaling mechanisms responsible for
angiogenesis during OM.
10. Mast cells
Mast cells are an integral part of innate immunity and are
deeply involved in the pathogenesis of OM.116–120 Mast cells are
predominantly found in the pars ﬂaccida compared to the pars
tensa of the tympanic membrane in the middle ear.121,122 They
have also been shown to be distributed throughout the tubotym-
panum in guinea pigs, in a decreasing gradient from the pharyngeal
to the tympanic oriﬁces, and in the ciliated epithelium and highly
vascularized parts of the middle ear.123 High densities of mast cells
have also been found in the ﬂoor of the rat tympanic bulla.124
Mast cell involvement in OM has been strongly linked to
histamine release. High levels of histamine in middle ear effusions
in various clinical studies and animal models have been correlated
with mast cell proliferation.125–128 In fact, increased histamine
release and thus mast cell proliferation, has been linked to mast
cells originating from the adenoids, as described in the adenoid
mediator release theory.129–131 One study found that the mast cell
count is higher in combined OME and adenoiditis than adenoiditis
alone. A greater hearing loss has been correlated with mast cell
density, thus revealing the complex nature of mast cell involve-
ment in OME.132
Mast cells appear to be involved in the longer clinical courses of
CSOM.133 But the relationship between mast cells and bacterial
infection in CSOM has not been entirely conclusive. Increased mast
cell activity has been shown in CSOM in which S. aureus and P.
aeruginosa are implicated, and in acute otitis media.134–136 Yet
Pajor et al. failed to show an increased density of mast cells in
CSOM due to bacterial infection.133 Ebmeyer et al. demonstrated
that NTHi infection causes middle ear mucosal inﬂammatory
changes in both wild-type and mast cell-deﬁcient mice.137
However the early response was signiﬁcantly blunted in mast
cell-deﬁcient mice. It has been suggested that mast cells may be
involved in the bone resorption observed in CSOM.138,139 Bone
resorption is the process by which osteoclasts break down bone
and release minerals, resulting in a transfer of calcium from bone
ﬂuid to the blood. It is an important aspect of CSOM contributing
to many complications of this disease such as ossicular erosion.
11. Natural killer cells
Natural killer (NK) cells are effector lymphocytes of the innate
immune system.140 While the importance of NK cells in innate
immune protection against tumors or viral infections is well
documented, their role in providing protection against bacteria is
still emerging. Jecker et al. demonstrated that although in healthy
rat middle ears there was no local proliferation of immune-
competent cells, approximately 15% of NK cells at day 5 of acute
OM were newly formed and likely to have been due to local
proliferation, while the remaining portion represented those
migrated from the outside mucosa.141 An increase in the number
of NK cells in the serum of CSOM children suggests a possible role
of these lymphocytes in protecting the middle ear against
infection.142 However, further studies are warranted to explore
the role of NK cells in the pathogenesis of acute and chronic OM.
12. Concluding remarks
OM is an important public health problem with substantial
economic and societal costs. It is a major global cause of hearing
impairment. Hearing loss caused by OM leads to speech difﬁcul-
ties, attention deﬁcit, language learning problems, and reading
problems, as well as cognitive and behavioral disorders in children.
In the past several years, considerable advances have been made in
understanding the role of innate immunity in the pathogenesis of
AOM. However, very few studies are available regarding the role of
innate immunity in CSOM. The rise in the incidence of CSOM cases,
emergence of antibiotic resistance, and potential ototoxicity of
antibiotics has created an immediate incentive to focus research
studies in this area so that novel therapeutic strategies may be
developed. There is a need to explore the role of PRRs like TLRs,
NLRs, RLRs, and CLRs in the pathophysiology of CSOM. Under-
standing the role of innate immunity in the pathogenesis of OM,
especially CSOM, will open up new avenues to design effective
non-conventional therapies against the disease. The antimicrobial
innate immune molecules (AIIMs) like b-defensins will be of
immense use to treat OM caused by antibiotic-resistant strains of
otopathogens. Implementing these approaches could decrease
physician visits, healthcare costs, antibiotic use, and surgery, and
at the same time increase quality of life for many OM patients.
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